Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 325

Sort by

Sort Order Select

Journal Articles

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Blood (2021) 138 (7): 571–583.

https://doi.org/10.1182/blood.2021010735

Published: 2021

Includes: Supplemental data

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Carlo Visco, Francesco Rodeghiero, Alessandra Romano, Federica Valeri, Michele Merli, Giulia Quaresimini, Stefano Volpetti, Roberto M. Santi, Giuseppe Carli, Elisa Lucchini, Francesco Passamonti, Alessandro Rambaldi, Giovanna Motta, Alessandra Borchiellini, Emanuele S. G. d’Amore, Marco Ruggeri

Blood (2019) 134 (20): 1708–1711.

https://doi.org/10.1182/blood.2019001617

Published: 2019

Includes: Supplemental data

Journal Articles

Spectrum and Clinical Significance of HLA Class I Alleles and Their Somatic Mutations in Immune Aplastic Anemia

Yoshitaka Zaimoku, MD PhD, Sharon D. Adams, MT, CHS (ABHI), Bhavisha A Patel, MD, Audrey Ai Chin Lee, MS, CHT (ABHI), Sachiko Kajigaya, PhD, Xingmin Feng, PhD, Olga Rios, RN, Holly DiFebo, RN, Lemlem Alemu, BS, Diego Quinones Raffo, MSc, Emma M. Groarke, MD, Willy A. Flegel, MD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 3738.

https://doi.org/10.1182/blood-2019-127359

Published: 2019

Journal Articles

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris Afanasyev, MD PhD, Sebastian Grosicki, MD PhD, Maria Socorro O Portella, MD MBA, Zewen Zhu, Dominik Selleslag, MD

Blood (2019) 134 (Supplement_1): 3740.

https://doi.org/10.1182/blood-2019-130309

Published: 2019

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study

Natalia Ruiz-Negron, PharmD, Jacob Crook, MStat, Matthew T. Rondina, MD, Pallavi Patwardhan, PhD, Qayyim Said, PhD, Isha Desai, MPH, Richard Nelson, PhD, Joanne LaFleur, PharmD, MSPH

Blood (2019) 134 (Supplement_1): 85.

https://doi.org/10.1182/blood-2019-121894

Published: 2019

Journal Articles

UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells

Tellechea Maria Florencia, MSc, Flavia S. Donaires, PhD, Tiago C. Silva, PhD, Lilian F. Moreira, PhD, Yordanka Armenteros, PhD, Rodrigo T. Calado, MD PhD

Blood (2019) 134 (Supplement_1): 2500.

https://doi.org/10.1182/blood-2019-127466

Published: 2019

Journal Articles

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

Zhi-Jian Liu, PhD, Emoke Deschmann, MD, Haley E. Ramsey, PhDMSc, Henry Feldman, Bethan Psaila, MD PhD, Nichola Cooper, MD MRCP, Evangelia Vlachodimtropoulou Koumoutsea, MBBS,PhDBSc, John B. Porter, MA MDFRCP FRCPath, James B. Bussel, MD, Michael Georgieff, MD, Martha Sola-Visner, MD

Blood (2019) 134 (Supplement_1): 2475.

https://doi.org/10.1182/blood-2019-131895

Published: 2019

Journal Articles

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Hanny Al-Samkari, MD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2356.

https://doi.org/10.1182/blood-2019-131215

Published: 2019

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience

Mohsen Saleh Elalfy, MD, Tamer Hassan, MD, Khalid Elsayh, MD, Mohamed Maebid, MD, Hoda Hassab, MD, Rasha Elashry, MD, Mona El ghamrawy, MD, Mahmoud Elhawy, MD, Marwa Zakaria, MD, Mohamed Elshanshory, MD

Blood (2019) 134 (Supplement_1): 4907.

https://doi.org/10.1182/blood-2019-121994

Published: 2019

Journal Articles

Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World

Jinsong JIA, MD PhD, Hao Jiang, Xiao Jun Huang

Blood (2019) 134 (Supplement_1): 5019.

https://doi.org/10.1182/blood-2019-131670

Published: 2019

Journal Articles

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

Wenrui Yang, MD, Bing Han, MD PhD, Hong Chang, MD, Bingyi Wu, MD, Fankai Meng, Dexiang Ji, MD, Yingmei Li, MD, Zhengjin Zheng, MD, Yan Fei, Jianping Shen, MD, Ping Hu, MD, Jianxiang Wang, MD, Fengkui Zhang, MD

Blood (2019) 134 (Supplement_1): 5020.

https://doi.org/10.1182/blood-2019-126441

Published: 2019

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

Low Dose of Eltrombopag with Long-Term Response in Children with Severe Aplastic Anemia, Less Morbi-Mortality Better Quality of Life

Norma C Lopez-Santiago, MD, Rogelio a Paredes Aguilera, MD, Angelica Cecilia Monsivais Orozco, MD, Maria De Lourdes Gonzalez Pedroza, MD, Gabriela Tavera Rodriguez, MD, Mara Toscano, MD

Blood (2019) 134 (Supplement_1): 5026.

https://doi.org/10.1182/blood-2019-130832

Published: 2019

Journal Articles

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Emily Molina, DO, MSPH, Gursharon Sanghera, MD, Patrick Hanley, MD, Rafat Ahmed, MD

Blood (2019) 134 (Supplement_1): 4900.

https://doi.org/10.1182/blood-2019-126200

Published: 2019

Journal Articles

Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single Institution

Weiwei Wang, PhD, Gabrielle Meyers, MD, Haibo Li, Ying Wang, Lisong Shen, MD PhD, Guang Fan, MD PhD

Blood (2019) 134 (Supplement_1): 948.

https://doi.org/10.1182/blood-2019-124896

Published: 2019

Journal Articles

Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial

Donald M. Arnold, MD, Nancy Heddle, MSc, Richard Cook, Cyrus C. Hsia, MDBSc,FRCPC, Mark Blostein, MDFRCPC, Erin Jamula, MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Yulia Lin, MD, Jeannine Kassis, MD, Loree Larratt, MD FRCP(C), Sufia Amini, MD, Martin R. Schipperus, Wendy Lim, MD MSc, Prakash Vishnu, MD, Margaret Warner, FRCPC, Julie Carruthers, MLT, B.Com(Hon), Shannon J Lane, MPH, Na Li, PhD, John G. Kelton, MD

Blood (2019) 134 (Supplement_1): 896.

https://doi.org/10.1182/blood-2019-122609

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Spectrum and Clinical Significance of HLA Class I Alleles and Their Somatic Mutations in Immune Aplastic Anemia

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study

UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience

Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

Low Dose of Eltrombopag with Long-Term Response in Children with Severe Aplastic Anemia, Less Morbi-Mortality Better Quality of Life

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single Institution

Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only